1. Search Result
Search Result
Results for "

CXCL 10

" in MedChemExpress (MCE) Product Catalog:

31

Inhibitors & Agonists

1

Biochemical Assay Reagents

2

Inhibitory Antibodies

3

Natural
Products

9

Recombinant Proteins

2

Antibodies

1

Click Chemistry

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99190

    BMS-936557; MDX-1100

    CXCR Inflammation/Immunology
    Eldelumab (BMS-936557) is a human anti-CXCL10 (IP-10) monoclonal antibody (IgG1 type). Eldelumab selectively binds to CXCL10 and blocks CXCL10-induced calcium flux and cell migration. Eldelumab can be used in studies of autoimmune and auto-inflammatory diseases such as rheumatoid arthritis, ulcerative colitis and crohn's disease .
    Eldelumab
  • HY-111149A
    PS372424 hydrochloride
    2 Publications Verification

    CXCR Inflammation/Immunology
    PS372424 hydrochloride, a three amino-acid fragment of CXCL10, is a specific human CXCR3 agonist with anti-inflammatory activity. PS372424 hydrochloride prevents human T-cell migration in a humanized model of arthritic inflammation .
    PS372424 hydrochloride
  • HY-15320
    NBI-74330
    5+ Cited Publications

    CXCR Inflammation/Immunology Endocrinology
    NBI-74330 is a potent antagonist for CXCR3, and exhibits potent inhibition of ( 125I)CXCL10 and ( 125I)CXCL11 specific binding with Ki of 1.5 and 3.2 nM, respectively.
    NBI-74330
  • HY-15319
    AMG 487
    Maximum Cited Publications
    33 Publications Verification

    CXCR Inflammation/Immunology Endocrinology Cancer
    AMG 487 is an orally active and selective antagonist of CXC chemokine receptor 3 (CXCR3) which inhibits the binding of CXCL10 and CXCL11 to CXCR3 with IC50s of 8.0 and 8.2 nM, respectively .
    AMG 487
  • HY-RS22949

    Small Interfering RNA (siRNA) Others

    Cxcl10 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cxcl10 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cxcl10 Rat Pre-designed siRNA Set A
    Cxcl10 Rat Pre-designed siRNA Set A
  • HY-RS03384

    Small Interfering RNA (siRNA) Others

    CXCL10 Human Pre-designed siRNA Set A contains three designed siRNAs for CXCL10 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CXCL10 Human Pre-designed siRNA Set A
    CXCL10 Human Pre-designed siRNA Set A
  • HY-RS16518

    Small Interfering RNA (siRNA) Others

    Cxcl10 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cxcl10 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cxcl10 Mouse Pre-designed siRNA Set A
    Cxcl10 Mouse Pre-designed siRNA Set A
  • HY-167884

    JAK Inflammation/Immunology
    PF-1367550 is a pan-JAK inhibitor. PF-1367550 can decrease the levels of release of CXCL9, CXCL10 and CXCL11 from primary airway epithelial cells .
    PF-1367550
  • HY-111149

    CXCR Inflammation/Immunology
    PS372424, a three amino-acid fragment of CXCL10, is a specific human CXCR3 agonist with anti-inflammatory activity. PS372424 prevents human T-cell migration in a humanized model of arthritic inflammation .
    PS372424
  • HY-P990639

    CXCR Inflammation/Immunology
    NI-0801 is a humanized antibody expressed in CHO, targeting CXCL10/IP-10. NI-0801 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for NI-0801 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    NI-0801
  • HY-15319A

    CXCR Cancer
    (±)-AMG 487 is a racemate of AMG 487. AMG 487 is an orally active and selective antagonist of CXC chemokine receptor 3 (CXCR3) which inhibits the binding of CXCL10 and CXCL11 to CXCR3 with IC50s of 8.0 and 8.2 nM, respectively .
    (±)-AMG 487
  • HY-152961

    STING Infection
    STING agonist-28 (CF510) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, increases phosphorylation of STING, TBK1 and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains .
    STING agonist-28
  • HY-152957

    STING Infection
    STING agonist-24 (CF504) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, increases phosphorylation of STING, TBK1 and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains .
    STING agonist-24
  • HY-152959

    STING Infection Cancer
    STING agonist-26 (CF508) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, increases phosphorylation of STING, TBK1 and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains .
    STING agonist-26
  • HY-152956

    STING Infection Cancer
    STING agonist-23 (CF502) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, increases phosphorylation of STING, TBK1 and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains .
    STING agonist-23
  • HY-152958

    STING Infection
    STING agonist-25 (CF505) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, increases phosphorylation of STING, TBK1 and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains .
    STING agonist-25
  • HY-122891
    SB02024
    1 Publications Verification

    PI3K CXCR STAT Cancer
    SB02024 is a potent and orally active VPS34 inhibitor. SB02024 inhibits Vps34 kinase activity. SB02024 induces CCL5 and CXCL10 via STAT1/IRF7. SB02024 shows anticancer activity .
    SB02024
  • HY-152237

    IKK Cancer
    TBK1-IN-1 is a potent and selective TANK binding kinase 1 (TBK1) inhibitor with an IC50 value of 22.4 nM. TBK1-IN-1 inhibits TBK1 downstream target genes cxcl10 and ifnβ expression. TBK1-IN-1 has anticancer activity .
    TBK1-IN-1
  • HY-W104821

    Keap1-Nrf2 Metabolic Disease
    Rosolic Acid is an activator of Nrf2, as well as its downstream targets. Rosolic Acid increases the levels of angiogenic factors, decreases inflammation (TNF-α and IL-1β) and apoptotic markers (CXCL10 and CCL2). Rosolic Acid restores the function of pancreatic cells and protects endothelial cells (ECs) from endoplasmic reticulum stressed .
    Rosolic acid
  • HY-173404

    STING Interleukin Related IFNAR TNF Receptor CXCR Inflammation/Immunology Cancer
    VB-85247 is a STING agonist. VB-85247 induces upregulation of inflammatory cytokines IFNα/β, TNFα, IL6, and CXCL10, as well as maturation and activation of dendritic cells by activating the STING pathway. VB-85247 can achieve regression of intrabladder tumors and can be used in bladder cancer research .
    VB-85247
  • HY-174136

    STING Inflammation/Immunology
    STING Degrader-2 (Compound SI-43) is a STING inhibitor and mutant-specific degrader. STING Degrader-2 can effectively inhibit cGAMP-induced STING activation and significantly reduce the release of IFN-β and CXCL-10. It inhibits the activity of STING by binding to two pockets of the STING dimer and induces proteasome-independent degradation of mutants STING S154 and STING M155 (DC50 values are 0.31 and 0.76 μM, respectively). STING Degrader-2 can be used to study STING-related autoimmune diseases .
    STING Degrader-2
  • HY-175739

    Mitochondrial Metabolism TNF Receptor IFNAR CXCR Neurological Disease
    TFAM activator 1 (Compound 2) is a Transcription Factor A, Mitochondrial (TFAM) activator. TFAM activator 1 has an anti-inflammatory and mitochondrial dysfunction restoration activity. TFAM activator 1 increases TFAM protein levels and mtDNA copy number and inhibits mtDNA stress-mediated inflammatory responses with reduced cytokine (TNF-α, CXCL-10 and IFN) production by preventing mtDNA escape into the cytosol. TFAM activator 1 significantly increases ATP level, reduces fibrotic markers and enhances Treg 240 function. TFAM activator 1 can be used for mitochondrial dysfunction, such as Parkinson’s and Alzheimer’s diseases research .
    TFAM activator 1
  • HY-162675

    GSK-3 Infection Neurological Disease Metabolic Disease Cancer
    COB-187 is a potent, ATP-competitive and selective inhibitor of GSK-3β. COB-187 inhibits GSK-3 through a reversible and Cysteine (Cys)-199-dependent mechanism. COB-187 inhibits LPS induced cytokine production and SARS-CoV-2 spike protein-induced CXCL10 production .
    COB-187
  • HY-113730

    CXCR Others
    VUF5834 is a non-peptide chemokine receptor CXCR3 antagonist with non-competitive antagonistic and inverse agonistic activities. VUF5834 blocks the effects of CXCL10 and CXCL11 on human CXCR3, exhibits non-competitive antagonistic and inverse agonistic properties to CXCR3, and, except for TAK-779, has a slightly lower affinity for rodent CXCR3 than for primate CXCR3.
    VUF5834
  • HY-124151

    2'-AMP; Adenosine 2'-phosphate; AMP 2'-phosphate

    Adenosine Receptor Endogenous Metabolite Neurological Disease
    Adenosine-2'-monophosphate (2'-AMP) is converted by extracellular 2’,3'-CAMP. Adenosine-2'-monophosphate is further metabolized to extracellular adenosine (a mechanism called the extracellular 2’,3’-cAMP-adenosine pathway). Adenosine-2'-monophosphate inhibits LPS-induced TNF-α and CXCL10 production via A2A receptor activation .
    Adenosine-2'-monophosphate
  • HY-176257

    STING Cancer
    STING agonist-44 (Compound 4) is a potent and selective STING agonist with an EC50 value of 5.68 for IRF induction in THP1 cells and 2.212 μM in RAW cells. STING agonist-44 activates the STING pathway, inducing the production of type I interferons and pro-inflammatory cytokines (e.g., CXCL10, TNFα). STING agonist-44 is promising for research of cancers .
    STING agonist-44
  • HY-N7688

    NO Synthase COX NF-κB CXCR Interleukin Related Indoleamine 2,3-Dioxygenase (IDO) Cardiovascular Disease Inflammation/Immunology Endocrinology
    Regaloside B is a phenylpropane. Regaloside B can be isolated from Lilium longiflorum. Regaloside B can inhibit the expression of VCAM-1, iNOS, and COX-2, with a p-p65/p-65 ratio. Regaloside B inhibits the mRNA of various chemokines and angiogenic factors (CXCL9, CXCL10, IL8, IDO). Regaloside B has anti-inflammatory activity. Regaloside B can be used for osteogenic differentiation research .
    Regaloside B
  • HY-165428

    CXCR Arrestin Inflammation/Immunology
    SCH-900875 is an orally active, brain-penetrant and selective CXCR3 receptor inhibitor, which also shows high selectivity over CXCR1 and CXCR2 receptors. SCH-900875 binds to CXCR3, blocking the binding of ligands CXCL9, CXCL10, and CXCL11, inhibiting downstream G protein and β-arrestin signaling pathways to suppress inflammatory cell migration. SCH-900875 is promising for research of autoimmune diseases (rheumatoid arthritis, multiple sclerosis) and inflammatory disorders (psoriasis, inflammatory bowel disease) .
    SCH-900875
  • HY-178207

    Ser/Thr Kinase CXCR TNF Receptor Interleukin Related Neurological Disease Inflammation/Immunology
    DF-003 is a selective, orally active, ATP-competitive, and brain-penetrant ALPK1 inhibitor. DF-003 potently inhibits human ALPK1 and ALPK1[T237M] with IC50s value of 1.5 nM and 16 nM. DF-003 exhibits more than 860-fold selectivity over the closest kinase. DF-003 inhibits TNF, CXCL10, or CXCL8 upregulation in HEK-293 cells. DF-003 can be used for the study of retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and headache (ROSAH) syndrome .
    DF-003
  • HY-172167

    PD-1/PD-L1 HDAC Inflammation/Immunology Cancer
    PD-L1/HDAC-IN-1 (Compound 14) is the inhibitor for PD-L1 and HDAC that inhibits PD-1/PD-L1 interaction, HDAC2 and HDAC3 with IC50 of 88.10, 27.98 and 14.47 nM, respectively. PD-L1/HDAC-IN-1 exhibits slight cytotoxicity in MCF-7 (IC50=19.34 μM). PD-L1/HDAC-IN-1 upregulates the expression of PD-L1 and CXCL10, promoting anti-tumour immune response by recruiting T-cell infiltration into TME .
    PD-L1/HDAC-IN-1
  • HY-178032

    PARP Apoptosis Reactive Oxygen Species (ROS) DNA/RNA Synthesis STING Cancer
    PARP1-IN-44, an Olaparib (HY-10162) derivative, is an orally active PARP1 inhibitor (IC50 = 0.6 nM), and also inhibits PARP2 (IC50 = 1.0 nM) and PARP7 (IC50 = 7.5 nM). PARP1-IN-44 has selective antiproliferative activity against BRCA-deficient cancer cells with minimal toxicity to normal cells. PARP1-IN-44 induces G2/M phase arrest, promotes apoptosis, elevates ROS levels, disrupts mitochondrial membrane potential. PARP1-IN-44 suppresses PARylation while increasing γH2AX accumulation. PARP1-IN-44 activates the cGAS-STING pathway, upregulating IFN-β and CXCL10 expression. PARP1-IN-44 enhancing CD8+ T cell infiltration in a CT26 tumor mouse model, demonstrating robust in vivo antitumor efficacy .
    PARP1-IN-44

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: